Key developments in the biotech sector highlight a breakthrough in treating pancreatic cancer with the experimental drug daraxonrasib, which has significantly improved survival rates for patients previously out of options. This progress reflects the strength of the U.S. healthcare system in transforming scientific insights into life-saving treatments. However, concerns grow over protectionist policies aimed at restricting collaboration with Chinese biotech firms, which could undermine American innovation and competitiveness, especially as many patents are set to expire by 2030. Experts urge a focus on fostering talent and funding basic research rather than isolating the industry, emphasizing that breakthroughs should ultimately prioritize patient access to life-saving therapies.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://fortune.com/2026/07/24/big-pharma-patent-cliff-cold-war-china-biotech/
